Recently, the methyltransferase DOT1L has emerged as a druggable target for this AML subgroup, since MLL fusions can recruit DOT1L and its mislocation induces aberrant H3K79 methylation and overexpression of leukemia relevant MLL target genes [4,5,7]. Here, KMT2A is linked to acute myeloid leukemia.